by Eric Quintanar
Daily Wire
Johnson & Johnson, the company that received emergency use authorization for the first one-shot COVID-19 vaccine in the United States, reportedly plans to conduct clinical trials that extend beyond adults, including to younger teenagers and then infants.
According to The New York Times, Food and Drug Administration officials who reviewed the emergency authorization material at a meeting Saturday discussed Johnson & Johnson’s future trial plans. Those plans include conducting trials for healthy children between 12 and 18 years old, and then all children up to 18 years old, including newborns, to analyze safety and immune responses to the COVID-19 vaccine.